Silence Therapeutics plc (SLN) DCF Valuation

Silence Therapeutics plc (SLN) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Silence Therapeutics plc (SLN) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain insight into your Silence Therapeutics plc (SLN) valuation analysis with our sophisticated DCF Calculator! Loaded with real SLN data, this Excel template enables you to adjust forecasts and assumptions, allowing you to accurately calculate the intrinsic value of Silence Therapeutics plc (SLN).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .3 6.9 15.6 22.0 31.9 54.7 93.7 160.7 275.6 472.7
Revenue Growth, % 0 2145.49 126.59 40.97 44.99 71.49 71.49 71.49 71.49 71.49
EBITDA -28.1 -44.6 -57.0 -60.1 -62.5 -54.7 -93.7 -160.7 -275.6 -472.7
EBITDA, % -9161.89 -648.46 -365.86 -273.61 -196.17 -100 -100 -100 -100 -100
Depreciation .6 .6 .5 .6 .6 12.8 22.0 37.7 64.6 110.8
Depreciation, % 197.54 9.05 3.44 2.75 1.96 23.44 23.44 23.44 23.44 23.44
EBIT -28.7 -45.2 -57.6 -60.7 -63.1 -54.7 -93.7 -160.7 -275.6 -472.7
EBIT, % -9359.43 -657.51 -369.3 -276.37 -198.13 -100 -100 -100 -100 -100
Total Cash 42.1 47.0 92.4 89.4 67.9 54.7 93.7 160.7 275.6 472.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 4.4 36.8 10.7 21.8 .3
Account Receivables, % 1441.8 534.88 68.36 99.09 0.89852
Inventories .0 1.9 .0 -20.6 .0 -7.3 -12.5 -21.4 -36.7 -63.0
Inventories, % 0 27.23 0.000008054772 -93.86 0 -13.33 -13.33 -13.33 -13.33 -13.33
Accounts Payable 2.2 2.9 5.1 4.0 3.3 22.2 38.1 65.3 111.9 191.9
Accounts Payable, % 733.61 41.7 32.74 18.2 10.36 40.6 40.6 40.6 40.6 40.6
Capital Expenditure .0 -.6 -1.7 -.6 -.1 -2.9 -5.0 -8.5 -14.6 -25.1
Capital Expenditure, % -3.69 -9.38 -10.75 -2.51 -0.17734 -5.3 -5.3 -5.3 -5.3 -5.3
Tax Rate, % 14 14 14 14 14 14 14 14 14 14
EBITAT -24.6 -40.9 -49.5 -51.9 -54.3 -47.4 -81.2 -139.3 -238.9 -409.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -26.1 -74.5 -20.4 -43.5 -53.6 -51.3 -71.9 -123.4 -211.6 -362.8
WACC, % 10.54 10.54 10.54 10.54 10.54 10.54 10.54 10.54 10.54 10.54
PV UFCF
SUM PV UFCF -558.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -370
Terminal Value -4,334
Present Terminal Value -2,626
Enterprise Value -3,184
Net Debt -68
Equity Value -3,117
Diluted Shares Outstanding, MM 37
Equity Value Per Share -84.02

What You Will Get

  • Authentic Silence Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
  • Immediate Valuation Updates: Automatic recalculations to assess the impact of changes on Silence Therapeutics' fair value.
  • Flexible Excel Template: Designed for quick edits, scenario analysis, and detailed forecasts.
  • Efficient and Precise: Avoid the hassle of building models from scratch while ensuring accuracy and adaptability.

Key Features

  • Customizable Research Inputs: Adjust essential parameters such as clinical trial timelines, market penetration rates, and cost structures.
  • Instant DCF Analysis: Quickly computes intrinsic value, NPV, and other key financial metrics.
  • High-Precision Estimates: Leverages Silence Therapeutics' (SLN) actual financial data for accurate valuation results.
  • Effortless Scenario Testing: Easily explore various assumptions and analyze different outcomes.
  • Efficiency Booster: Streamline the valuation process without the hassle of constructing intricate models from the ground up.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Silence Therapeutics plc (SLN) data.
  • Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Silence Therapeutics plc (SLN) intrinsic value.
  • Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.

Why Choose This Calculator?

  • Designed for Experts: A sophisticated tool utilized by biostatisticians, CFOs, and healthcare consultants.
  • Accurate Data: Silence Therapeutics plc’s (SLN) historical and projected financials are preloaded for precision.
  • Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance makes the process straightforward.

Who Should Use This Product?

  • Investors: Evaluate Silence Therapeutics’ valuation before making stock transactions.
  • CFOs and Financial Analysts: Enhance valuation workflows and validate financial forecasts.
  • Startup Founders: Understand the valuation methods applied to biotech firms like Silence Therapeutics.
  • Consultants: Provide comprehensive valuation reports for clients in the healthcare sector.
  • Students and Educators: Utilize current data to learn and teach valuation strategies in biotechnology.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
  • Real-World Data: Silence Therapeutics plc’s (SLN) historical and projected financials preloaded for analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.

No products were found matching.